Federal Contractor Profile
Venatorx Pharmaceuticals INC
$299M obligated·7 awards·2 agencies·3 NAICS
Federal Contracts
Showing award actions 1–50 of 50 funded award actions, most recent first.
- Contracts with positive obligations
- 7
- Funded award actions shown
- 50
- Obligations shown
- $299M
- Awarding agencies
- 2
This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.
Award data as of July 31, 2026. Source: USAspending federal award records.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Jul 31, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00016 | 541715 | TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. | $256K |
| Aug 27, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119C00007 | 541714 | VENATORX PHARMACEUTICALS, INC. | $7.0M |
| Aug 20, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $370K |
| Jul 1, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00016 | 541715 | TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. | $9.4M |
| Sep 15, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123C00050 | 541714 | VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS. | $20M |
| Jul 11, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119C00007 | 541714 | VENATORX PHARMACEUTICALS, INC. | $8.4M |
| Jun 7, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $3.3M |
| May 16, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00016 | 541715 | TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. | $4.7M |
| Sep 27, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122C00080 | 541714 | VENATORX PHARMACEUTICALS: ANTIBIOTIC FOR AMR AND BIOTHREAT PATHOGENS | $72M |
| Sep 22, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119C00007 | 541714 | VENATORX PHARMACEUTICALS, INC. | $5.0M |
| Sep 16, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00016 | 541715 | TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. | $4.5M |
| Jun 22, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119C00007 | 541714 | VENATORX PHARMACEUTICALS, INC. | $9.5M |
| May 26, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00016 | 541715 | TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. | $3.0M |
| Mar 4, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $2.3M |
| Sep 16, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $4.0M |
| Aug 13, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119C00007 | 541714 | VENATORX PHARMACEUTICALS, INC. | $16M |
| May 12, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119C00007 | 541714 | VENATORX PHARMACEUTICALS, INC. | $6.3M |
| Apr 22, 2021 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA117C0070 | 541711 | PENICILLIN BINDING PROTEINS IGF::OT::IGF | $1.9M |
| Apr 15, 2021 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA117C0070 | 541711 | PENICILLIN BINDING PROTEINS IGF::OT::IGF | $1.0M |
| Mar 9, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $440K |
| Sep 23, 2020 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA117C0070 | 541711 | PENICILLIN BINDING PROTEINS IGF::OT::IGF | $1.0M |
| Sep 3, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $1.9M |
| Jun 29, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00016 | 541715 | TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. | $3.2M |
| Apr 22, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $1.2M |
| Apr 20, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119C00007 | 541714 | VENATORX PHARMACEUTICALS, INC. | $23M |
| Feb 24, 2020 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA117C0070 | 541711 | PENICILLIN BINDING PROTEINS IGF::OT::IGF | $1.9M |
| Feb 22, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119C00007 | 541714 | VENATORX PHARMACEUTICALS, INC. | $11M |
| Dec 13, 2019 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA117C0070 | 541711 | PENICILLIN BINDING PROTEINS IGF::OT::IGF | $1.3M |
| Aug 28, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $1.4M |
| Jul 17, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119C00007 | 541714 | VENATORX PHARMACEUTICALS, INC. | $21M |
| May 29, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $7.2M |
| May 6, 2019 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA117C0070 | 541711 | PENICILLIN BINDING PROTEINS IGF::OT::IGF | $2.5M |
| Mar 27, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $2.5M |
| Jan 30, 2019 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA117C0070 | 541711 | PENICILLIN BINDING PROTEINS IGF::OT::IGF | $1.4M |
| Dec 12, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $1.2M |
| Sep 19, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $2.8M |
| Jun 21, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201300019C | 541711 | IGF::OT::IGF DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES | $1.3M |
| May 22, 2018 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA117C0070 | 541711 | PENICILLIN BINDING PROTEINS IGF::OT::IGF | $2.6M |
| Mar 8, 2018 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA117C0070 | 541711 | PENICILLIN BINDING PROTEINS IGF::OT::IGF | $400K |
| Feb 26, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $4.0M |
| Dec 22, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201300019C | 541711 | IGF::OT::IGF DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES | $1.3M |
| Nov 29, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201300019C | 541711 | IGF::OT::IGF DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES | $1.5M |
| Sep 12, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $9.2M |
| Aug 18, 2017 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA117C0070 | 541711 | PENICILLIN BINDING PROTEINS IGF::OT::IGF | $700K |
| Jul 17, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201300019C | 541711 | IGF::OT::IGF DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES | $2.8M |
| May 26, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201300019C | 541711 | IGF::OT::IGF DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES | $2.0M |
| Mar 22, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201300019C | 541711 | IGF::OT::IGF DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES | $1.2M |
| Sep 19, 2016 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600029C | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $7.1M |
| Sep 2, 2016 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201300019C | 541711 | IGF::OT::IGF DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES | $3.6M |
| Jun 8, 2016 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201300019C | 541711 | IGF::OT::IGF DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES | $3.6M |
Get Alerted Before Venatorx Pharmaceuticals INC's Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start for free